Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1Phase 2 Interventional

Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)

ClinicalTrials.gov ID: NCT01234025

Public ClinicalTrials.gov record NCT01234025. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 12:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1b/2 Study of Docetaxel and Prednisone, With or Without ISIS 183750 (an eIF4E Inhibitor), in Patients With Castrate-Resistant Prostate Cancer

Study identification

NCT ID
NCT01234025
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Enrollment
113 participants

Conditions and interventions

Interventions

  • ISIS EIF4E Rx Drug
  • Prednisone Drug
  • Docetaxel Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2010
Primary completion
Apr 30, 2013
Completion
Nov 30, 2013
Last update posted
Oct 5, 2023

2010 – 2013

United States locations

U.S. sites
11
U.S. states
9
U.S. cities
11
Facility City State ZIP Site status
Highlands Oncology Group Fayetteville Arkansas 72703
San Bernardino Urological Associates San Bernardino California 92404-4816
Fort Range Cancer Center Fort Collins Colorado 80528
Norwalk Hospital- Whittingham Cancer Center Norwalk Connecticut 06850
Lakeland Regional Cancer Center Lakeland Florida 33805
University of Miami, Miller School of Medicine - Sylvester Comprehensive Cancer Center Miami Florida 33136
Central Baptist Hospital Clinical Research Center Lexington Kentucky 40503
Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center Shreveport Louisiana 71103
St. Luke's - Roosevelt Hospital Center New York New York 10019
James P. Wilmont Cancer Center - University of Rochester Medical Center Rochester New York 14642
Gabrail Cancer Center Canton Ohio 44718

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01234025, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 5, 2023 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01234025 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →